Overview

Efficacy of DLBS-32 in Subjects With Type-II Diabetes Mellitus

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate clinical efficacy and safety of DLBS 32 in the management of subjects with type-II-diabetes mellitus and to determine the minimal effective dose of DLBS 32 for subjects with type-II-diabetes mellitus.
Phase:
Phase 2
Details
Lead Sponsor:
Dexa Medica Group